General Information of Drug (ID: DMJ36YH)

Drug Name
ACE-011 Drug Info
Synonyms
116496-76-5; 4-Acetamido-3-ethoxynitrobenzene; N-(2-ethoxy-4-nitrophenyl)acetamide; Acetamide,N-(2-ethoxy-4-nitrophenyl)-; 2'-ETHOXY-4'-NITROACETANILIDE; CDS1_004703; AC1MEGDI; ACMC-20c3rb; CBMicro_030367; 2-Ethoxy-4-nitroacetanilide; Oprea1_342150; DivK1c_005743; ACE011; SCHEMBL2204761; KS-00002AMW; CTK4A9819; DTXSID60387001; XZWVZJDHIDYKPB-UHFFFAOYSA-N; MolPort-000-279-575; ZX-AT005552; ZINC5061120; OR9529; AKOS001044796; PS-6223; VZ36467; MCULE-3006561606; AB07920; AS02565; KB-71958; CC-31292; AJ-53053; Acetamide, N-(2-ethoxy-4-nitrop
Indication
Disease Entry ICD 11 Status REF
Anemia 3A00-3A9Z Phase 1 [1]
Cross-matching ID
PubChem CID
2877953
CAS Number
CAS 116496-76-5
TTD Drug ID
DMJ36YH

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
M7824 DMJCULI Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
TEW-7197 DM2LBC3 Myeloproliferative neoplasm 2A20 Phase 2 [2]
Bintrafusp alfa DMB9LRJ Non-small-cell lung cancer 2C25 Phase 2 [3]
NIS793 DM8LBYT Pancreatic ductal carcinoma 2C10.0 Phase 2 [2]
LY2382770 DMH3YKJ Diabetic kidney disease GB61.Z Phase 2 [4]
Fresolimumab DMFZ084 Brain cancer 2A00 Phase 2 [5]
BCA101 DMM0VBU Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
GS-1423 DMS25DL Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
AVID200 DMZ39T6 Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
RG6440 DMVQXFH Aggressive cancer 2A00-2F9Z Phase 1 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Transforming growth factor beta (TGFB) TTO3HT7 NOUNIPROTAC Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of Acceleron Pharma (2011).
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. J Thorac Oncol. 2020 Jul;15(7):1210-1222.
4 A phase I dose-escalation study to a predefined dose of a transforming growth factor-1 monoclonal antibody (TM1) in patients with metastatic cancer. Int J Oncol. 2014 Dec;45(6):2221-31.
5 Focal Irradiation and Systemic TGF Blockade in Metastatic Breast Cancer. Clin Cancer Res. 2018 Jun 1;24(11):2493-2504.
6 ClinicalTrials.gov (NCT04429542) Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors. U.S. National Institutes of Health.
7 Clinical pipeline report, company report or official report of Agenus.
8 TGF signaling underlies hematopoietic dysfunction and bone marrow failure in Shwachman-Diamond Syndrome. J Clin Invest. 2019 Jun 18;129(9):3821-3826.
9 Clinical pipeline report, company report or official report of Roche